Qifu Huazhuo formula for gout recurrence prevention: an interim analysis combining clinical outcomes with proteomic and metabolomic profiling.

ABSTRACT:

Purpose

Gout is a chronic disease caused by the deposition of monosodium urate crystals in joints and tissues. The Qifu Huazhuo (QFHZ) Formula has shown effectiveness and safety in the management of gout. However, the role of QFHZ in the mitigation of gout needs to be further explored.

Materials and methods

UHPLC-MS/MS was used to identify potential metabolites of QFHZ. Then we conducted a midpoint evaluation of the clinical study on the treatment of gout with QFHZ formula. The clinical study was a monocenter, open-label, randomized controlled trial. Eligible participants were allocated to TM, WM and TWM three groups in random. Participants in TM, WM and TWM group were received QFHZ (250 mL/dose, twice daily, oral), febuxostat (40 mg/dose, once daily, oral) and combination o

SUBMITTER: Shen Z 

PROVIDER: S-EPMC12582547 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature